Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AQ002M
- Development stage
- Phase 4
- Lead developer
- Aquilon Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
AQ002M (also known as AQ002&3M) is an investigational, ultra-low-dose fixed combination of the inhaled corticosteroid (ICS) budesonide and the long-acting beta-agonist (LABA) formoterol. Developed by Aquilon Pharma, AQ002M is formulated using the company's proprietary cyclodextrin-based excipient technology (HP-Betadex), which enhances the solubility of the active ingredients in water. This formulation is specifically optimized for delivery via a Soft Mist Inhaler (SMI), aiming to improve lung deposition, prolong airway activity, and minimize local and systemic side effects at lower doses. It is currently in early-stage development for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
- Other names
- budesonide + formoterol Soft Mist Inhalerultra-low dose budesonide + formoterol
02
Targets
ADRB2 (β2)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on AQ002M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AQ002M.